Navigation Links
BioTrends Releases Fourth Annual Nephrology TreatmentTrends Publication Highlighting Market Trends for Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism
Date:1/28/2008

EXTON, Pa., Jan. 28 /PRNewswire/ -- BioTrends Research Group, Inc. released its Fourth Annual Nephrology TreatmentTrends Publication, a syndicated report offering comprehensive insight into the management of renal anemia and bone and mineral metabolism in Chronic Kidney Disease (CKD). The report is based on responses to an online survey, completed by 305 clinical nephrologists in the US, during December 2007.

In the anemia market, the vast majority of nephrologists report being aware of safety concerns surrounding the use of ESAs and 80% indicate that these safety issues have had an impact on their management of anemia, primarily reflected in their lower hemoglobin targets. More than three quarters of the nephrologists state that they do not anticipate any further changes. Amgen's Epogen continues its position as market share leader in dialysis while Aranesp and Procrit continue to battle for market leader position in pre-dialysis.

In the IV Iron market, use continues to be primarily reserved for hemodialysis patients with the majority of nephrologists viewing American Regent's Venofer and Watson's Ferrlecit as interchangeable. AMAG Pharmaceuticals recently filed an NDA for a new form of intravenous iron, ferumoxytol, which could be commercially available in the second half of 2008. Current familiarity with ferumoxytol is low, with 68% indicating that they are "not at all familiar" with the product.

In the phosphate binder market, nephrologists seem to be in agreement about the importance of controlling phosphorus in pre-dialysis patients, with 62% reporting "phosphorus" as the most important level to keep within target range (over PTH and calcium). This has not, however, translated into increased use of binders over the past year. Binder preference also remains similar to last year with calcium-based binders (such as Fresenius Medical Care's PhosLo) dominating 2:1 in the pre-dialysis setting, whereas in the dialysis market, the shift to non-calcium agents (such as Genzyme's Renagel and Shire's Fosrenol) continues, with Renagel maintaining its position as market leader. While perceived need for a new phosphate binder is high, knowledge of new binders in development is low. Genzyme recently received approval for Renvela (sevelamer carbonate) which is expected to launch in the first quarter of 2008.

In the management of secondary hyperparathyroidism, nephrologists report an increased use of Vitamin D in both the dialysis and CKD populations which has grown consistently since 2004. While the majority of nephrologists view Abbott's Zemplar and Genzyme's Hectorol as interchangeable, Zemplar continues to grow its share in dialysis and CKD, currently leading Hectorol in both markets. In dialysis patients, use of Amgen's Sensipar has also increased in the past year and nephrologists expect continued growth with share rising from 29% to 35% in the next three months. Sensipar, however, tends to be reserved for patients with PTH greater than 500 pg/dL, and is typically used in combination with Vitamin D.

About BioTrends Research Group, Inc.

BioTrends Research Group, Inc. (http://www.bio-trends.com) provides syndicated and custom market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please contact us at (610) 363-3872 or http://www.bio-trends.com.

All company, brand, or product names contained in this document may be trademarks of their respective holders.


'/>"/>
SOURCE BioTrends Research Group, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Vital Images Releases Next Generation Enterprise-Wide Solutions Featuring Vitrea(R) 4.0 and ViTALConnect(R) 4.1
2. Quigley Corporation Releases Update on Quigley Pharmas Phase IIb Clinical Study of QR-333 in Diabetic Peripheral Neuropathy
3. Boston Scientific Releases Remote Monitoring Data from its Wireless LATITUDE(R) Patient Management System
4. ARUP Laboratories Releases ARUP Consult(R) 2.0
5. Rabobank Releases Annual North American Food & Agribusiness Outlook
6. National Nanotechnology Initiative releases new strategic plan
7. Seven Summits Research Releases Alerts on XOM, MER, DRYS, CSC, and PDLI
8. CellCyte Genetics Corp. Responds to Plaintiff Law Firm Press Releases
9. Memry Corporation Announces Preliminary Fiscal Fourth Quarter and 2007 Revenue
10. ThermoGenesis Corp. to Announce Fourth Quarter and Year End Results for Fiscal Year 2007 on September 12, 2007
11. Dynatronics to Release Fourth Quarter and Year-end Results Friday, September 14, 2007; Conference Call set for 1:00 p.m. ET
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 23, 2016   Boston Biomedical , ... compounds designed to target cancer stemness pathways, announced ... granted Orphan Drug Designation from the U.S. Food ... gastric cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin ... to inhibit cancer stemness pathways by targeting STAT3, ...
(Date:6/23/2016)... HOUSTON , June 23, 2016 ... agreement with the Cy-Fair Sports Association to serve ... of the agreement, Houston Methodist Willowbrook will provide ... education and connectivity with association coaches, volunteers, athletes ... partner with the Cy-Fair Sports Association and to ...
(Date:6/23/2016)... -- The Biodesign Challenge (BDC), a university competition that asks ... systems and biotechnology, announced its winning teams at the ... York City . The teams, chosen ... MoMA,s Celeste Bartos Theater during the daylong summit. Keynote ... of architecture and design, and Suzanne Lee , ...
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the sample tracking ... Arkansas State Crime Laboratory, has joined STACS DNA as a Field Application Specialist. ... Jocelyn Tremblay, President and COO of STACS DNA. “In further expanding our capacity as ...
Breaking Biology Technology:
(Date:4/26/2016)... LONDON , April 26, 2016 ... EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... a partnership to integrate the Onegini mobile security ... (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The ... enhanced security to access and transact across channels. ...
(Date:4/15/2016)... -- A new partnership announced today will help life ... a fraction of the time it takes today, ... insurance policies to consumers without requiring inconvenient and ... rapid testing (A1C, Cotinine and HIV) and higi,s ... pulse, BMI, and activity data) available at local ...
(Date:4/13/2016)... April 13, 2016  IMPOWER physicians supporting Medicaid patients ... a new clinical standard in telehealth thanks to a ... the higi platform, IMPOWER patients can routinely track key ... body mass index, and, when they opt in, share ... visit to a local retail location at no cost. ...
Breaking Biology News(10 mins):